Osvaldo Gonzalez, MD
Endocrinology, Diabetes & Metabolism · Suitland, MDNPI 1104828748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,645 of the $30,954 with a category attached, or 86.1%. It is spread thinly across 50 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $8,587 and has fallen 54.0% since, to $3,947 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 975 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$5K
- Mannkind Corporation$3K
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$2K
- AstraZeneca$2K
- Amgen$2K
- plus $14K from 44 others
What the payments were for
- Consulting fees$1,7005%
- Speaking & faculty fees$1,6085%
- Travel & lodging$7492%
- Food & beverage$26,64586%
- Education$1921%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$2,777
- TEPEZZA$1,720
- CeQur Simplicity$1,217
- Omnipod$674
- FARXIGA$602
- Korlym$569
- SOLIQUA 100/33$432
- DEXCOM G7 GSS (161)$402
- iLet Bionic Pancreas$357
- Synthroid$351
- DEXCOM CGM$238
- Ozempic$222
- DEXCOM G6 TRANSMITTER$140
- RYBELSUS$125
- Kerendia$125
- TZIELD$125
- Wegovy$122
- V-GO$121
- iLet Insulin Infusion Kit Inset$119
- iLet Insulin Infusion Kit Contact Detach$119
How this compares
$30,954 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $631,984 |
| JardianceEmpagliflozin | 242 | $380,921 |
| MounjaroTirzepatide | 227 | $294,905 |
| TrulicityDulaglutide | 107 | $206,434 |
| FarxigaDapagliflozin Propanediol | 163 | $193,933 |
| Tresiba Flextouch U-100Insulin Degludec | 151 | $147,043 |
| RybelsusSemaglutide | 59 | $116,302 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $92,866 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 44 | $65,708 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $59,863 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 39 | $57,763 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $44,193 |
| JanuviaSitagliptin Phosphate | 33 | $38,881 |
| ProliaDenosumab | 19 | $32,511 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $28,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,368 | $753,671390 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $4,698 | $514,187366 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $1,328 | $446,630286 claims |
| AstraZenecaFarxiga | $2,290 | $193,933163 claims |
| MerckJanuvia | $494 | $38,88133 claims |
| AmgenProlia | $2,267 | $32,51119 claims |
| Johnson & JohnsonInvokana | $151 | $26,28116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,354 | $22,47515 claims |
| AbbVieSynthroid | $893 | $8,817111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $1,000 | $6,645439 claims |
| PfizerEliquis | $58 | $5,84715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Suitland
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.